Orqis tests CHF recovery system in US trial
This article was originally published in Clinica
Executive Summary
The US FDA has given Orqis Medical the green light to conduct a pivotal clinical trial of its catheter-based cardiac recovery system for treating congestive heart failure (CHF). The MOMENTUM trial will test the company's system, called Cancion, in up to 200 CHF patients at 40 centres. Cancion is the first therapy for CHF based on continuous aortic blood flow augmentation to the descending aorta, claims the Lake Forest, California firm. It is designed to allow the heart to rest while it recovers from an acute decompensation event.
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.